Corteva price target raised to $95 from $89 at RBC Capital

RBC Capital analyst Arun Viswanathan raised the firm’s price target on Corteva (CTVA) to $95 from $89 and keeps an Outperform rating on the shares as part of a broader research note previewing Q1 results for Specialty Chemicals names. The firm continues to see company-specific items as major drivers for improvement in 2026, with a preference for names with minimal impact from Middle East conflict and higher oil cost, the analyst tells investors in a research note.